256 related articles for article (PubMed ID: 34007050)
1. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
van der Zwet JCG; Buijs-Gladdines JGCAM; Cordo' V; Debets DO; Smits WK; Chen Z; Dylus J; Zaman GJR; Altelaar M; Oshima K; Bornhauser B; Bourquin JP; Cools J; Ferrando AA; Vormoor J; Pieters R; Vormoor B; Meijerink JPP
Leukemia; 2021 Dec; 35(12):3394-3405. PubMed ID: 34007050
[TBL] [Abstract][Full Text] [Related]
2. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
3. STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of
Van der Zwet JCG; Cordo' V; Buijs-Gladdines JGCAM; Hagelaar R; Smits WK; Vroegindeweij E; Graus LTM; Poort V; Nulle M; Pieters R; Meijerink JPP
Haematologica; 2023 Mar; 108(3):732-746. PubMed ID: 35734930
[TBL] [Abstract][Full Text] [Related]
4. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
[TBL] [Abstract][Full Text] [Related]
5. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
7. Overcoming Steroid Resistance in Pediatric Acute Lymphoblastic Leukemia-The State-of-the-Art Knowledge and Future Prospects.
Kośmider K; Karska K; Kozakiewicz A; Lejman M; Zawitkowska J
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409154
[TBL] [Abstract][Full Text] [Related]
8. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
Zenatti PP; Ribeiro D; Li W; Zuurbier L; Silva MC; Paganin M; Tritapoe J; Hixon JA; Silveira AB; Cardoso BA; Sarmento LM; Correia N; Toribio ML; Kobarg J; Horstmann M; Pieters R; Brandalise SR; Ferrando AA; Meijerink JP; Durum SK; Yunes JA; Barata JT
Nat Genet; 2011 Sep; 43(10):932-9. PubMed ID: 21892159
[TBL] [Abstract][Full Text] [Related]
10. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
11. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
13. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
15. ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.
Munck JM; Berdini V; Bevan L; Brothwood JL; Castro J; Courtin A; East C; Ferraldeschi R; Heightman TD; Hindley CJ; Kucia-Tran J; Lyons JF; Martins V; Muench S; Murray CW; Norton D; O'Reilly M; Reader M; Rees DC; Rich SJ; Richardson CJ; Shah AD; Stanczuk L; Thompson NT; Wilsher NE; Woolford AJ; Wallis NG
Mol Cancer Ther; 2021 Oct; 20(10):1757-1768. PubMed ID: 34330842
[TBL] [Abstract][Full Text] [Related]
16. Bim protein degradation contributes to cisplatin resistance.
Wang J; Zhou JY; Wu GS
J Biol Chem; 2011 Jun; 286(25):22384-92. PubMed ID: 21561860
[TBL] [Abstract][Full Text] [Related]
17. α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK).
Naci D; El Azreq MA; Chetoui N; Lauden L; Sigaux F; Charron D; Al-Daccak R; Aoudjit F
J Biol Chem; 2012 May; 287(21):17065-17076. PubMed ID: 22457358
[TBL] [Abstract][Full Text] [Related]
18. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
[TBL] [Abstract][Full Text] [Related]
19. Targeting steroid resistance in T-cell acute lymphoblastic leukemia.
De Smedt R; Morscio J; Goossens S; Van Vlierberghe P
Blood Rev; 2019 Nov; 38():100591. PubMed ID: 31353059
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
